This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Ohr Pharmaceutical Inc.

Drug Names(s): AVR118, OHR118, Product R, Reticulose

Description: AVR118 is a new formulation of Reticulose, a drug that was marketed in the United States during the 1940's through the early 1960's. In 1962, the FDA issues regulations which caused Reticulose and other drugs to be classified as a New Drug requiring FDA approval prior to any sales in the United States. After that, Reticulose was not marketed in the U.S. or other developed countries. While there have been no controlled clinical trials of Reticulose, there was largely anecdotal published data between 1951 and 1970 indicating it was effective in treating a number of viruses, such as Asian Influenza, Viral Pneumonia, Virus Infectious Hepatitis, Mumps, Encephalitis, Herpes Simplex and Herpes Zoster.

AVR118 consists of a mix of 14 nucleoside derivatives and a complex aggregate of peptides. Like Reticulose, it is made from casein, beef peptone, RNA, bovine serum albumin, and sodium hydroxide. However, AVR118 involves an improved process for a more purified product.

A number of preclinical effects have been noted with AVR118. It stimulates peripheral blood mononuclear cells to produce the proinflammatory cytokines IFN-y, IL-1b, IL-6 and TNF-a.

It also binds to adenosine receptors in vitro and increases cAMP release. Its anti-anorexic activity may involve receptor binding in the gut and in the functional pathway of orexin A, which stimulates food intake.

Deal Structure: The founders of Advanced Viral Research acquired the original compound, Reticulose, in 1984 through the purchase of Key Pharmaceuticals, and founded Advanced Viral Research in 1985 for the purpose of producing Reticulose.

Ohr and AVR
In March 2009, Ohr Pharmaceutical acquired AVR118 from Advanced Viral Research.

OHR/AVR118 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug